PharmaCyte Biotech, Inc.
NASDAQ Capital MarketTotal Valuation
PharmaCyte Biotech, Inc. carries a market capitalization of 5.22M, placing it among publicly traded companies globally. Its enterprise value stands at -28.06M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.22M |
| Enterprise Value | -28.06M |
Share Statistics
PharmaCyte Biotech, Inc. currently has 10.74M shares outstanding.
| Shares Outstanding | 10.74M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.23 |
| P/TBV Ratio | 0.23 |
| P/FCF Ratio | -1.07 |
| P/OCF Ratio | -1.07 |
Financial Position
PharmaCyte Biotech, Inc. maintains a current ratio of 45.28, meaning it holds 45.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 45.28 |
| Quick Ratio | 45.16 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -46.03 |
| Return on Assets (ROA) | -38.12 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -8.24 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
PharmaCyte Biotech, Inc.'s stock has declined approximately -48.30517% over the past 52 weeks. The 50-day moving average sits at 0.60, while the 200-day moving average is 0.73.
| Beta (5Y) | N/A |
| 52-Week Price Change | -48.30517% |
| 50-Day Moving Average | 0.60 |
| 200-Day Moving Average | 0.73 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -5.30M, while operating income came in at -5.30M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -5.30M |
| Pretax Income | -19.42M |
| Net Income | -19.42M |
| EBITDA | -5.30M |
| EBIT | -5.30M |
| Earnings Per Share (EPS) | -2.55 |
Balance Sheet
Total book value stands at 33.71M, with working capital of 36.59M providing operational flexibility.
| Cash & Cash Equivalents | 37.08M |
| Total Debt | N/A |
| Net Debt | -18.60M |
| Equity (Book Value) | 33.71M |
| Book Value Per Share | 3.14 |
| Working Capital | 36.59M |
Cash Flow
PharmaCyte Biotech, Inc. produced -5.15M in operating cash flow over the past twelve months.
| Operating Cash Flow | -5.15M |
| Capital Expenditures | N/A |
| Free Cash Flow | -5.15M |
| FCF Per Share | -0.68 |
Dividends & Yields
The company's payout ratio of 1.41 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | 1.41 |
| Shareholder Yield | -84.91 |
| FCF Yield | -93.68 |
Stock Splits
PharmaCyte Biotech, Inc.'s most recent stock split took place on July 12, 2021 with a 1550:1 split ratio.
| Last Split Date | 7/12/2021 |
| Split Ratio | 1550:1 |
Scores
PharmaCyte Biotech, Inc. posts an Altman Z-Score of -2.17, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.17 |